Urology
Volume 72, Issue 5 , Pages 966-967, November 2008

Case for Pharmacotherapy Development for Underactive Bladder

  • Michael B. Chancellor

      Affiliations

    • Neurourology Program, Department of Urology, William Beaumont Hospital, Royal Oak, Michigan
    • Corresponding Author InformationReprint requests: Michael Chancellor, M.D., Neurourology Program, Department of Urology, William Beaumont Hospital, 438 Medical Office Building, 3535 West 13 Mile Road, Royal Oak, MI48073
    • ,
  • Jonathan Kaufman

      Affiliations

    • Frontier Group, Pittsburgh, Pennsylvania

Received 7 March 2008; accepted 24 April 2008. published online 09 September 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 M. B. Chancellor is a consultant to Allergan, Astellas, Cook, Merck, Pfizer, Proctor and Gambles, and Wyeth; and J. Kaufman is a consultant to the Frontier Group.

PII: S0090-4295(08)00529-3

doi:10.1016/j.urology.2008.04.041

Urology
Volume 72, Issue 5 , Pages 966-967, November 2008

Article Tools